- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ipsen SA (IPN)
Ipsen SA stock price live, this page displays EPA IPN stock exchange data. View the IPN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ipsen SA real time stock price chart below.
What Is the Ipsen SA Stock Price Today?
The Ipsen SA stock price today is 116.80.
What Is the Stock Symbol for Ipsen SA?
The stock symbol for Ipsen SA is ""IPN.""
What Stock Exchange Does Ipsen SA Trade On?
Ipsen SA is listed and trades on the Paris stock exchange.
Is Ipsen SA a Good Stock to Buy?
Determining whether Ipsen SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPN quote. (ISIN: FR0010259150)
What Is the Ipsen SA Stock Price Today?
The Ipsen SA stock price today is 116.80.
What Is the Stock Symbol for Ipsen SA?
The stock symbol for Ipsen SA is ""IPN.""
What Stock Exchange Does Ipsen SA Trade On?
Ipsen SA is listed and trades on the Paris stock exchange.
Is Ipsen SA a Good Stock to Buy?
Determining whether Ipsen SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPN quote. (ISIN: FR0010259150)
116.80
+0.70(+0.60%)
Closed·
Fair Value
An estimate of a Ipsen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
116.10
118.50
52 wk Range
87.95
125.60
IPN Scorecard
Full Analysis
Net income is expected to grow this year
IPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Ipsen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
116.10118.50
52 wk Range
87.95125.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.21%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.21%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IPN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Ipsen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
127.00
Upside
+8.73%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
- Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Sutro Biopharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Ipsen SA Company Profile
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Ipsen SA Earnings Call Summary for Q1/2025
- Q1 2025 revenue of $918.8M exceeded forecasts by 13.7%, with total sales up 11.6% YoY; stock fell 3.23% despite strong earnings
- Oncology sales grew 8%, rare disease saw significant growth, neuroscience approached double-digit growth; company maintains PFIC leadership
- Ipsen reaffirmed 2025 guidance: total sales growth over 5% at constant exchange rates, core operating margin exceeding 30% of sales
- CEO highlighted strong top-line growth, increased investment in launches and pipeline; key milestones include EMA decision on Cabometyx
- Challenges: generic competition for Somatuline, potential US aesthetics market softening; manufacturing primarily in Europe mitigates tariff concerns
Last Updated: 16/04/2025, 14:02
Read Full TranscriptCompare IPN to Peers and Sector
Metrics to compare | IPN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 21.6x | 22.5x | −0.5x | |
PEG Ratio | −0.63 | 0.09 | 0.00 | |
Price/Book | 2.3x | 3.5x | 2.6x | |
Price / LTM Sales | 2.6x | 2.1x | 3.3x | |
Upside (Analyst Target) | 3.3% | −3.8% | 38.7% | |
Fair Value Upside | Unlock | 21.4% | 5.0% | Unlock |
Analyst Ratings
7 Buy
6 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 127.00
(+8.73% Upside)
Earnings
Latest Release
Jul 31, 2025
EPS / Forecast
4.00 / --
Revenue / Forecast
901.00M / 917.00M
People Also Watch
FAQ
What Stock Exchange Does Ipsen Trade On?
Ipsen is listed and trades on the Paris Stock Exchange stock exchange.
What Is the Stock Symbol for Ipsen?
The stock symbol for Ipsen is "IPN."
What Is the Ipsen Market Cap?
As of today, Ipsen market cap is 9.65B.
What Is Ipsen's Earnings Per Share (TTM)?
The Ipsen EPS (TTM) is 5.42.
When Is the Next Ipsen Earnings Date?
Ipsen will release its next earnings report on 21 Oct 2025.
From a Technical Analysis Perspective, Is IPN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Ipsen Stock Split?
Ipsen has split 0 times.
How Many Employees Does Ipsen Have?
Ipsen has 5358 employees.
What is the current trading status of Ipsen (IPN)?
As of 27 Aug 2025, Ipsen (IPN) is trading at a price of 116.80, with a previous close of 116.10. The stock has fluctuated within a day range of 116.10 to 118.50, while its 52-week range spans from 87.95 to 125.60.
What Is Ipsen (IPN) Price Target According to Analysts?
The average 12-month price target for Ipsen is EUR127, with a high estimate of EUR155 and a low estimate of EUR105. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +8.73% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.